Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TXNRD1 | Q16881 | 18/20 | 0.48 |
| ▸ | GSR | P00390 | 1/20 | 0.43 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.42 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23825276 | 0.85 | TXNRD1 (0.46) | TXNRD1GSRS1PR4MAPTS1PR1 | |
| SCHEMBL22013249 | 0.82 | TXNRD1 (0.51) | TXNRD1GSRS1PR4MAPTS1PR1 | |
| SCHEMBL29692796 | 0.82 | TXNRD1 (0.51) | TXNRD1GSRS1PR4MAPTS1PR1 | |
| SCHEMBL2520856 | 0.82 | TXNRD1 (0.51) | TXNRD1GSRS1PR4MAPTS1PR1 | |
| SCHEMBL16648934 | 0.79 | TXNRD1 (0.53) | TXNRD1GSRS1PR4MAPTS1PR1 | |
| SCHEMBL14358106 | 0.78 | POLB (0.36) | MAPT | |
| SCHEMBL3219042 | 0.75 | TXNRD1 (0.52) | TXNRD1GSRS1PR4MAPTS1PR1 | |
| SCHEMBL21617705 | 0.75 | TXNRD1 (0.51) | TXNRD1GSRS1PR4MAPTS1PR1 | |
| SCHEMBL621047 | 0.74 | TXNRD1 (0.54) | TXNRD1GSRS1PR4MAPTS1PR1 | |
| SCHEMBL16649146 | 0.73 | TXNRD1 (0.50) | TXNRD1GSRS1PR4MAPTS1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113166141-B | Hexa-membered and hexa-membered heterocyclic compounds and application thereof as protein receptor kinase inhibitors | 上海轶诺药业有限公司 | 2022-07-22 | — | — | CN | disclosed |
| US-20220017512-A1 | SIX-MEMBERED AND SIX-MEMBERED HETEROCYCLIC COMPOUND AND USES THEREOF SERVING AS PROTEIN RECEPTOR KINASE INHIBITOR | SHANGHAI ENNOVABIO PHARMACEUTICALS CO., LTD. (CN) | 2022-01-20 | — | — | US | disclosed |
| US-20220017512-A1 | SIX-MEMBERED AND SIX-MEMBERED HETEROCYCLIC COMPOUND AND USES THEREOF SERVING AS PROTEIN RECEPTOR KINASE INHIBITOR | SHANGHAI ENNOVABIO PHARMACEUTICALS CO., LTD. (CN) | 2022-01-20 | — | — | US | disclosed |
| EP-3882247-A1 | SIX-MEMBERED AND SIX-MEMBERED HETEROCYCLIC COMPOUND AND USES THEREOF SERVING AS PROTEIN RECEPTOR KINASE INHIBITOR | Shanghai Ennovabio Pharmaceuticals Co., Ltd. (CN) | 2021-09-22 | — | — | EP | disclosed |
| EP-3882247-A1 | SIX-MEMBERED AND SIX-MEMBERED HETEROCYCLIC COMPOUND AND USES THEREOF SERVING AS PROTEIN RECEPTOR KINASE INHIBITOR | Shanghai Ennovabio Pharmaceuticals Co., Ltd. (CN) | 2021-09-22 | — | — | EP | disclosed |
| CN-113166141-A | Hexa-membered and hexa-membered heterocyclic compounds and application thereof as protein receptor kinase inhibitors | 上海轶诺药业有限公司 | 2021-07-23 | — | — | CN | disclosed |
| WO-2020098723-A1 | SIX-MEMBERED AND SIX-MEMBERED HETEROCYCLIC COMPOUND AND USES THEREOF SERVING AS PROTEIN RECEPTOR KINASE INHIBITOR | 上海轶诺药业有限公司 | 2020-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220017512-A1 | SIX-MEMBERED AND SIX-MEMBERED HETEROCYCLIC COMPOUND AND USES THEREOF SERVING AS PROTEIN RECEPTOR KINASE INHIBITOR | GRK6, ERBB2, ERBB3 | TXNRD1 1172/4885GSR 2758/4885S1PR4 2640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.